- The U.S. Food and Drug Administration accepted Filament Health’s (NEO:FH) application for its psilocybin drug candidate to treat substance disorders
- The company filed an Investigational New Drug (IND) application, which had also been submitted to Health Canada with no objection from that department
- PEX010 is a botanical psilocybin drug that is being studied by 24 research institutions and licensing partners in Canada, the U.S., Europe, and Israel for conditions including alcohol use disorder, depression, and coma
- Filament Health Corp. last traded at $0.085 per share
The U.S. Food and Drug Administration accepted Filament Health’s (NEO:FH) application for its psilocybin drug candidate to treat substance disorders.
The company filed an Investigational New Drug (IND) application, which had also been submitted to Health Canada with no objection from that department.
PEX010 is a botanical psilocybin drug that is being studied by 24 research institutions and licensing partners in Canada, the U.S., Europe, and Israel for conditions including alcohol use disorder, depression, and coma.
This allows the company to begin research in the U.S. with Filament’s botanical psilocybin drug candidate.
“The toxic drug crisis is a significant, growing problem in both Canada and the United States,” Filament Health’s CEO and Co-Founder, Benjamin Lightburn said in a news release. “We believe that botanical PEX010 could offer a solution. PEX010 is already under investigation for opioid use disorder in Canada and this milestone allows us to build on that progress in the United States. Congratulations to the team at Filament for a major regulatory achievement.”
Filament Health is a clinical-stage natural psychedelic drug development company.
Filament Health Corp. last traded at $0.085 per share.
Join the discussion: Find out what everybody’s saying about this stock on the Filament Health Bullboard, and check out the rest of Stockhouse’s stock forums and message boards.
The material provided in this article is for information only and should not be treated as investment advice. For full disclaimer information, please click here.